Obesity Drug Discoveries: what the future holds
| Publication Date | August 2007 |
|---|---|
| Publisher | Espicom |
| Product Type | Report |
| Pages | 116 |
| ISBN Number | 978-1-85822-294-3 |
| Product Code | ESP00347 |
Buy this product or for assistance call +44 20 7060 7474
Summary
This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the anti-infective sector. The report includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. The report covers 8 key therapy areas (alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS, musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by major product. Click here for more information. This chapter is available separately.
The anti-infectives market is the fifth largest therapeutic category. We estimate that anti-infectives grossed sales of US$28.5 billion in 2005, with a further US$16 billion being derived from hospital-based use and OTC. The majority of prescription-based sales were derived from the US (around 50%) compared to 22% in Europe and Japan. However, growth in Europe at over 5% exceeded that of the US and Japan compared with around 3%.
Please Note: The publisher will not fulfil orders to a personal email address, you must supply a work or business address.
Content
- Executive summaryWhat is obesity?
- Defining obesity
- What causes obesity?
- What effects does obesity have?
- Figure 1: Effects of obesity on health
- Table 1. Relative risks of health problems associated with obesity
- The scale of the problem
- Prevalence of obesity
- Figure 2. Estimated global prevalence of obesity
- Highest prevalence of obesity
- Prevalence in the US
- Prevalence in the UK
- Prevalence in Europe
- Prevalence in Asia
- Prevalence in developing countries
- Highest prevalence of obesity
- Figure 3. Percentage of households having both underweight and overweight members in seven countries
- Figure 4. Country comparison - percentage of adults with normal BMI
- Childhood and future obesity
- Figure 5. Percentage of population that is overweight
- Figure 6. Predicted prevalence of obesity by 2025
- The economic burden
- US
- UK
- Europe
- Developing Countries
- The obesity therapy market
- Competitor ratio analysis
- Table 2. Competitor ratio analysis summary
- Obesity management
- Controlling energy balance
- Achieving weight loss
- Table 3. The benefits of a 10kg weight loss
- Lifestyle modifications
- Behaviour therapy
- Pharmacotherapy
- Surgery
- Approved drugs for obesity management
- Table 4. History of drug treatments for obesity
- Table 5. Anti-obesity drugs approved for short-term use
- Table 6. Anti-obesity drugs approved for long-term use
- Acomplia
- Approval History
- Key Markets
- Key Agreements
- Clinical Trial Data
- Safety Issues
- Further Development
- Sales
- Sales Forecast
- Figure 7. Acomplia reported and projected sales, 2006A-2012E (EUR million)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Meridia/Reductil
- Approval History
- Key Markets
- Key Agreements
- Clinical Trial Data
- Table 7. Percentage change in subject's body weight at varying doses of sibutramine
- Table 8. Health profile of subjects losing at least 5 per cent of body weight
- Safety Issues
- Further Development
- Xenical/alli
- Approval History
- Key Markets
- Key Agreements
- Patent History
- Clinical Trial Data
- Safety Issues
- Further Development
- Sales
- Sales Forecast
- Figure 8. Reported and projected sales of Xenical 2001A-2011E
- Regulatory authority guidelines for drug approval
- Approval for additional indications
- Potential new drugs
- Table 9. Novel drugs in development by Phase
- Table 10. Novel drugs in development by company
- Drugs in clinical development
- Figure 9. Estimated launch dates for profiled drugs
- Beta3 adrenergic receptor modulators
- Table 11. Beta3 adrenergic receptor modulators in development
- KR P-204 (N-5984)
- Safety Issues
- Competitors
- Launch Prediction
- Cannabinoid receptor modulators
- Table 12. Cannabinoid receptor modulators in development:
- CP-945,598
- Safety Issues
- Competitors
- Launch Prediction
- taranabant
- Safety Issues
- Competitors
- Launch Prediction
- AVE 1625
- Safety Issues
- Competitors
- Launch Prediction
- SLV 319
- Key Agreements
- Safety Issues
- Competitors
- Launch Prediction
- Digestive inhibitors/lipid metabolism modulators
- Table 13. Digestive inhibitors/lipid metabolism modulators in development cetilistat
- Key Agreements
- Clinical Trial Data
- Safety Issues
- Further Developments
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- 869682
- Safety Issues
- Competitors
- Launch Prediction
- Histaminergic system modulators
- Table 14. Histaminergic system modulators in development
- OBE 101
- Table 15. Properties of OBE101 and histamine compared
- Key Agreements
- Clinical Trial Data
- Safety Issues
- Table 16. Adverse effects of OBE101 when compared to anti-obesity medications currently in use
- Patent History
- Further Development
- Competitors
- Launch Prediction
- Hormone analogues
- Table 17. Hormone analogues in development pramlintide
- Clinical Trial Data
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- liraglutide
- Clinical Trial Data
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- obinepitide
- Patent History
- Clinical Trial Data
- Further Development
- Safety Issues
- Competitors
- Launch Prediction
- PYY 3-36
- Key Agreements
- Patent History
- Clinical Trial Data
- Further Development
- Safety Issues
- Competitors
- Launch Prediction
- Monoamine reuptake inhibitors/5-HT receptor modulators
- Table 18. Monoamine reuptake inhibitors/5-HT receptor modulators in developmentlorcaserin
- Patent History
- Clinical Trial Data
- Table 19. Incidence of FDA-defined valvulopathy
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- tesofensine
- Clinical Trial Data
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Risks associated with drug development in therapeutic class
- Neuropeptide receptor modulators
- Table 20. Neuropeptide receptor modulators in development S-2367
- Clinical Trial Data
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Combination drugs
- Table 21. Combination drugs in development
- Contrave
- Patent History
- Clinical Trial Data
- Further Developments
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Qnexa
- Clinical Trial Data
- Further Development
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- pramlintide+phentermine/sibutramine
- Safety Issues
- Competitors
- Launch Prediction
- Empatic
- Patent History
- Clinical Trial Data
- Table 22. Percentage change in body weight at week 24
- Safety Issues
- Launch Prediction
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Recently-terminated p rogrammes
- AMG 076
- AOD 9604
- Clinical Trial Data
- CP-741952
- CYT 009-GhrQb
- Clinical Trial Data
- oleoyl-estrone
- Patent History
- Clinical Trial Data
- Further Development
- PF-431499
- The f uture of obesity treatment
- Towards an all-encompassing cure; targeting the metabolic syndrome?
- Recent advances and future developments
- CD 36
- Targeting ghrelin
- Vaccines
- Gene therapy
- RNA interference
- Conclusions
- Sources
- Espicom sources
- Others
Delivery Details
PDF:Delivered by email usually within 4 to 8 UK business hours.
Related Products
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharma Chemicals
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Meet Us
Jobs
Contact Us
Categories and Subcategories











